A Phase I Study of AG-348 in Healthy Volunteers

Inclusion Criteria: * Healthy adult male or female subjects 18 - 60 years, in good general health who are able to understand consent and complete all study procedures. * Female subjects of non-child bearing potential (surgically sterile or post-menopausal as confirmed by age \[over 50 years\], amenorrhea for ≥12 consecutive months and FSH). * Male subjects who are not vasectomized must agree to use contraception up to 30 days after dosing. * Subjects with body weight ≥50 kg; BMI ≥18.5 and ≤32 kg/m2. * Subjects who are non-smokers and have not used nicotine-containing products for at least 3 months prior to screening. * Subjects must be willing to refrain from caffeine- or xanthene-containing products (coffee, tea, chocolate) for 48 hours prior to dosing through discharge from the clinical facility. * Subjects must agree to refrain from strenuous exercise starting 72 hours prior to admission through final follow-up visit. * Subjects must refrain from use of alcohol starting 7 days (14 days for red wine) prior to admission through final follow-up visit. * Subjects must agree not to donate blood products for duration of study participation. Exclusion Criteria: * Subjects who have previously received AG-348. * Subjects with clinically relevant screening laboratory tests. * Female subjects who are not post-menopausal. * Subjects with recent use of prescription, over the counter (OTC), herbal and/or dietary medications and/or supplements. * Male subjects with QTcF interval ECG \> 450 msec,or female subjects with QTcF interval ECG \> 470 msec. * Subjects with a history of a serious mental illness. * Subjects with a clinically relevant medical history or pre-existing medical condition that would interfere with the absorption, metabolism or excretion of the study drug. * Subjects with a history of any primary malignancy (cancer). Exceptions are certain skin cancers, cervical cancer in situ or other cancers that have been curatively treated without evidence of disease for a minimum of 1 year. * Subjects with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. * Subjects who are positive for hepatitis B, hepatitis C or HIV. * Subjects who have undergone surgery 6 months prior to screening. * Subjects who have a history of illicit drug use or alcoholism within the last year. * Subjects who are participating in other concurrent clinical trial of an investigational drug, or have received another investigational agent within the last 2 months. * Subjects with any conditions which would make the subject unsuitable for enrollment, or could interfere with the subject's participation in or completion of the study.